If LRRK2 critically modifies initial progression of motoric deficits in PD, for example, by promoting survival of dopaminergic neurons, a primary endpoint could be used, such as measuring the time interval from diagnosis of PD to the requirement of dopaminergic therapy. Here, LRRK2 is linked to Parkinson disease.